Lumiphore, based in Berkeley, United States, is an early-stage radiopharmaceutical company focused on leveraging proprietary lanthanide technology. Their core mission is to enhance human health through innovative diagnostic and therapeutic constructs. Utilizing novel macrocyclic BiFunctional Chelate (mBFC) technology, Lumiphore aims to create best-in-class medicines by applying their extensive expertise in metals in medicine to both existing and novel cancer-targeting agents.
Lumiphore's key achievements include the development of constructs that enable rapid, room-temperature chelation of a wide range of promising radioisotopes. This innovation positions them at the forefront of radiopharmaceutical advancements, potentially transforming cancer diagnostics and treatment. Their deep domain knowledge and decades of chelation expertise have made significant impacts in the field, contributing to the creation of more effective and accessible cancer therapies.
